¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"no observed adverse effect level"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • fat blood level
    Áö¹æÇ÷Ãþ
  • firing level
    ¹ßÈ­¼öÁØ
  • ground water level
    ÁöÇϼö³ôÀÌ
  • level
    1. ¼öÁØ 2. Ãþ 3. Ä¡ 4. ³óµµ
  • level of significance
    À¯ÀǼöÁØ
  • maximal expiratory level
    Ãִ볯¼û¼öÁØ, ÃÖ´ëÈ£±â°ª
  • maximal inspiratory level
    ÃÖ´ëµé¼û¼öÁØ, ÃÖ´ëÈí±â°ª
  • maximum permissible level
    ÃÖ´ëÇã¿ë¼öÁØ
  • maximum safe intensity level
    ÃÖ´ë¾ÈÀü°­µµ¼öÁØ
  • noise level
    ¼ÒÀ½¼öÁØ, ÀâÀ½µµ
  • peak level
    ÃÖ°íÄ¡
  • permissible radiation exposure level
    Çã¿ë¹æ»ç¼±ÇÇÆø¼±·®
  • saturation sound pressure level
    Æ÷È­¼Ò¸®¾Ð¼öÁØ, Æ÷È­À½¾Ð¼öÁØ
  • sound level meter
    1. À½·®¼öÁذè 2. ¼ÒÀ½°è
  • sound pressure level
    ¼Ò¸®¾Ð¼öÁØ, À½¾Ð¼öÁØ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • reversing effect
    ¿ªÀüÈ¿°ú
  • shielding effect
    Â÷ÆóÈ¿°ú, °¡¸²È¿°ú
  • stochastic effect
    È®·ü·ÐÀûÈ¿°ú
  • synergistic effect
    »ó½ÂÈ¿°ú
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • effective perceived noise level
    ½ÇÈ¿°¨¼ö¼ÒÀ½¼öÁØ, ½ÇÁ¦°¨°¢¼ÒÀ½
  • electronic energy level
    ÀüÀÚ¿¡³ÊÁö¼öÁØ
  • fat blood level
    Áö¹æÇ÷Ãþ
  • firing level
    ¹ßÈ­¼öÁØ
  • ground water level
    ÁöÇϼö³ôÀÌ
  • level
    ¼öÁØ, Ãþ, Ä¡, ³óµµ
  • level
    Æ÷È­¼Ò¸®¾Ð¼öÁØ
  • level of significance
    À¯ÀǼöÁØ
  • maximal expiratory level
    Ãִ볯¼û¼öÁØ
  • maximal inspiratory level
    ÃÖ´ëµé¼û¼öÁØ
  • maximum permissible level
    ÃÖ´ëÇã¿ë¼öÁØ
  • maximum safe intensity level
    ÃÖ´ë¾ÈÀü°­µµ¼öÁØ
  • noise level
    ¼ÒÀ½¼öÁØ, ÀâÀ½µµ
  • peak level
    ÃÖ°íÄ¡
  • permissible radiation exposure level
    Çã¿ë¹æ»ç¼±ÇÇÆø¼±·®
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • glucose level
    Æ÷µµ´çÄ¡<--ÁØÀ§>
  • ground water level
    ÁöÇϼö³ôÀÌ.
  • intensity level
    °­µµ¼öÁØ(Ë­öôâ©ñÞ).
  • power level
    ÆÄ¿ì¾î·¹º§.
  • Bernouilli effect
    º£¸£´©ÀÌ È¿°ú
  • Bohr effect
    º¸¾Æ È¿°ú(üùÍý)
  • CPE=£¾cytopathogenic effect
    ¼¼Æ÷º´º¯È¿°ú.
  • CPE=£¾cytopathogenic effect
    ¼¼Æ÷º´º¯È¿°ú.
  • Cytopath(ogen)ic effect, CPE
    ¼¼Æ÷º´º¯È¿°ú
  • Donnan effect
    µ·³­È¿°ú
  • Doppler effect
    µµÇ÷¯ È¿°ú
  • Fahraeus-Lindqvist effect
    ÆÄ·¹¿ì½º-¸°Äûºñ½ºÆ® È¿°ú(üùÍý)
  • Fenn effect
    Ææ È¿°ú(üùÍý)
  • Gibbs effect
    ±é½º È¿°ú
  • HIV effect
    HIV È¿°ú<ÀÛ¿ë>
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • antimicrobial level
    Ç×±ÕÁ¦Ä¡<¼öÁØ(â©ñÞ)>
  • audiometric level
    û·Â, û·Â·¹º§
  • blood alcohol level = blood alcohol concentration
    Ç÷Áß¾ËÄڿóóµµ
  • blood enzyme level
    Ç÷ÁßÈ¿¼Ò³óµµ.
  • blood oxygenation level dependant contrast
    Ç÷Áß »ê¼ÒÄ¡ ÀÇÁ¸ ´ëÁ¶µµ
  • blood oxygenation level dependant(BOLD)
    Ç÷Áß »ê¼ÒÄ¡ ÀÇÁ¸
  • carinal level
    ºÐ±â ´ë
  • control level
    °ü¸®¼öÁØ(Ë´ËöËàÌ¡).
  • decision level
    °áÁ¤¼öÁØ
  • developmental level
    ¹ß´Þ¼öÁØ(Û¡Ó¹â©ñÞ)
  • drug level monitoring
    ¾à¹°³óµµ°¨½Ã, ¾à¹°³óµµÃøÁ¤
  • effective perceived noise level =EPNDB
    ½ÇÈ¿°¨¼ö¼ÒÀ½(Ëà̷˧ËÛËÛËô)·¹ º§.
  • electronic energy level
    ÀüÀÚ¿¡³ÊÁöÁØÀ§(¡­ñÞêÈ).
  • excess level
    °úÀ×¼öÁØ
  • fasting blood sugar (level) =FBS
    °øº¹½ÃÇ÷´ç(Ä¡).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • dispersion effect
    "ºÐ»ê È¿°ú(ÝÂߤüùÍý), (ÔÒ) dispersion forces"
  • Dorn effect
    "µ· È¿°ú(üùÍý), (ÔÒ) sedimentation potential"
  • drag effect
    ²ø¸² È¿°ú(üùÍý) (ÔÒ) solvent drag
  • dual-effect mutant
    ÀÌÁßÈ¿°ú º¯ÀÌü(ì£ñìüùÍýܨì¶ô÷)
  • electrochromic effect
    Àü±âº¯»ö È¿°ú(ï³Ñ¨Ü¨ßäüùÍý)
  • electrophoretic effect
    Àü±â¿µµ¿ È¿°ú(ï³Ñ¨ç¶ÔÑüùÍý)
  • electroviscous effect
    Àü±âÁ¡¼º È¿°ú(ï³Ñ¨ïÄàõüùÍý)
  • enhancement effect
    Áõ°­ È¿°ú (ñòË­üùÍý)
  • extrinsic Cotton effect
    ¿ÜÀμº(èâì×àõ) ÄÚÆ° È¿°ú(üùÍý)
  • Faraday effect
    ÆÐ·¯µ¥ÀÌ È¿°ú(üùÍý)
  • field effect
    ÀåÈ¿°ú(íÞüùÍý)
  • founder effect
    ½ÃÁ¶ È¿°ú(ã·ðÓüùÍý)
  • glucose effect
    ±Û·çÄÚ½º È¿°ú(üùÍý)
  • Haldane effect
    Ȧµ¥ÀÎ È¿°ú(üùÍý)
  • heterotropic effect
    ÀÌÁú È¿°ú(ì¶òõüùÍý)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Bernouilli effect
    º£¸£´©ÀÌÈ¿°ú
  • biologic effect
    »ý¹°ÇÐÀûÈ¿°ú
  • biological effect
    »ý¹°ÇÐÀûÈ¿°ú
  • cavitation effect
    °øµ¿È¿°ú
  • direct piezoelectric effect
    Á÷Á¢¾ÐÀüÈ¿°ú
  • Doppler effect
    µµÇ÷¯È¿°ú
  • effect
    È¿°ú, ÀÛ¿ë
  • entry slice effect
    À¯ÀԴܸéÈ¿°ú
  • fast scan effect
    °í¼Ó½ºÄµÈ¿°ú
  • Gibbs effect
    ±é½º È¿°ú
  • gradient echo effect
    °æ»ç¿¡ÄÚÈ¿°ú
  • gradient induced phase shift effect
    °æ»çÀ¯µµ À§»óº¯À§È¿°ú
  • halo effect
    ´Þ¹«¸®È¿°ú
  • immediate effect
    Áﰢȿ°ú, Áï½ÃÈ¿°ú
  • in-flow effect
    À¯ÀÔ È¿°ú
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
LEL lower explosive limit; lowest effect level
HCG, hCG Human Chorionic Gonadotropin; »ç¶÷À¶¸ð¼º¼º¼±ÀÚ±ØÈ£¸£¸ó
  1. Placental Glycoprotein Hormone
&nbs...
CCL carcinoma cell line; certified cell line; Charcot-Leyden crystal; continuing care level; critical ca...
CL capillary lumen; cardiolipin; cell line; centralis lateralis; chemiluminescence; chest and left arm ...
SAL sensorineural activity level; sterility assurance level; suction-assisted lipectomy
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
LOEC Lowest observed effect concentrations
NOEC No observed effect concentration
NOEL No Observable Effect Level
ADE Adverse Drug Event
ADR Adverse Drug Reaction
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • elevated transaminase level

    elevation (°Å»ó, »ó½Â, À¶±â, °íÀ§

    À§·Î ¿Ã¶ó°¨. ¾î´À ÇÑ ºÎºÐÀÌ ³ôÀÌ ¼Ú¾Æ ¿À¸§. µé¾î¿Ã¸° ºÎÀ§, ¶Ç´Â Á»´õ ³ôÀº Á¡.
  • fasting blood sugar level
    °øº¹ ½Ã Ç÷´çÄ¡
  • level
    ¼öÁØ, ±íÀÌ, Ä¡, ´ÜÀ§, Ãþ, À§, ³ôÀÌ, ¹üÀ§, ¼öÁرâ, ÁØÀ§
  • maximal expiratory level
    ÃÖ´ë È£±âÀ§
  • maximal inspiratory level
    ÃÖ´ë Èí±âÀ§
  • mucosal level
    Á¡¸· ¼öÁØ
  • permissible radiation exposure level
    »ç¼± ³ëÃâ Çã¿ë·®
  • subconscious level
    ÀáÀç ÀÇ½Ä ¼öÁØ
  • substrate level phosphorylation
    ±âÁú±Þ ÀλêÈ­
  • ultrastructural level
    Ãʹ̼¼ ±¸Á¶Àû ¼öÁØ
    ÀÎü¸¦ ±¸¼ºÇÏ´Â ÃÖ¼Ò ¹Ì¼¼ ÀÔÀÚÀÇ ¼öÁØ. ±¤ÇÐÇö¹Ì°æÀÇ ÇØ»ó·ÂÀ» ³ÑÀº ÃÊÇö¹Ì°æÀ̳ª ÀüÀÚÇö¹Ì°æÇÏ¿¡¼­ óÀ½À¸·Î º¸ÀÌ´Â ±¸Á¶.
  • additive effect
    ÷°¡ È¿°ú, »óÇÕÈ¿°ú
    ¼­·Î ´Ù¸¥ µÎ ¾à¹°À» ¾î´À Á¤µµ±îÁöÀÇ ¿ë·® ¹üÀ§ ³»¿¡¼­ µ¿½Ã¿¡ Åõ¿©ÇÒ °æ¿ì ±× È¿°ú´Â µÎ ¾à¹°À» °¢°¢ ´Üµ¶À¸·Î Åõ¿©ÇÏ¿´À» ¶§ ³ªÅ¸³ª´Â ÀÛ¿ëÀÇ »ê¼úÀûÀÎ ÇÕ¸¸À¸·Î ³ªÅ¸³ª´Â ÀÛ¿ë.
  • adrenal suppressive effect
    ºÎ½Å ¾ïÁ¦ È¿°ú
  • air gap effect
    °ø±â °£°Ý È¿°ú
  • allogenic effect
    µ¿Á¾ ¼¼Æ÷ ¹ÝÀÀ È¿°ú
    µ¿Á¾ÀÇ ¸²ÇÁ°í¸¦ Åõ¿©ÇÔÀ¸·Î½á ºñƯÀÌÀûÀ¸·Î ¸é¿ª¹ÝÀÀÀÌ Áõ°¡µÇ±âµµ ÇÏ°í ¾ïÁ¦µÇ±âµµ ÇÏ´Â Çö»ó. Áõ°¡µÈ °æ¿ì¸¦ Á¤ÀÇ allogenic È¿°ú, ¾ïÁ¦µÈ °æ¿ì¸¦ ºÎÀÇ allogenic È¿°ú¶ó°í ÇÑ´Ù.
  • anticurare effect
    Ç×Å¥¶ó·¹ ÀÛ¿ë
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
gray level also gray value <microscopy> The brightness of pixels in a digitised video image, commonly expressed in integers ranging from 0 (black) to 255 (white) for an 8-bit digital signal.
(05 Aug 1998)
gray level histogram <microscopy> In digital image processing, a histogram that depicts the number of pixels at each gray value. The histogram can be used to measure the areas that have given ranges of gray values or to adjust image contrast by histogram stretching or equalisation.
See: Image histogram.
(05 Aug 1998)
Clark's level The level of invasion of primary malignant melanoma of the skin; limited to the epidermis, I; into the underlying papillary dermis, II; to the junction of the papillary and reticular dermis, III; into the reticular dermis, IV; into the subcutaneous fat, V. The prognosis is worse with each successive deeper level of invasion.
(05 Mar 2000)
cohb level A blood test which is performed on an arterial specimen and is a measurement of the amount of carbon monoxide which is present and bound to haemoglobin. This is an important test to diagnosis carbon monoxide toxicity (smoke inhalation). Normal carboxyhaemoglobin may be from 3% to as high as 12% in heavy smokers.
Symptoms of carbon monoxide poisoning begin at about 20% carboxyhaemoglobin.
(27 Sep 1997)
white level <microscopy> Also reference white level. The IEEE scale, or voltage level, of the video picture signal that corresponds to a specified maximum limit for white peaks.
(05 Aug 1998)
window level The CT number setting in Hounsfield units of the midpoint of the window width, which is the gray scale of the image; a typical window level for imaging the lungs if -500; for the abdomen, 0.
(05 Mar 2000)
hearing level The measure of the status of hearing as read directly on the hearing loss scale of an audiometer; described in decibels as a deviation from a standard value for zero on the audiometer.
(05 Mar 2000)
serum iron level A test that measures the amount of iron (Fe ++) in the blood. The test is performed when iron deficiency is suspected. Normal serum iron is 60 to 170 mcg/dl. Increased levels may be seen in the following: haemochromatosis, haemolysis, haemolytic anaemia, hepatitis, liver necrosis, haemosiderosis, iron poisoning and lead toxicity. Lower than normal levels are seen in chronic GI blood loss, iron deficiency anaemia, insufficient dietary iron, malabsorption, chronic heavy menstrual bleeding, nephrosis and late pregnancy.
(27 Sep 1997)
sound pressure level A measure of sound energy relative to 0.0002 dynes/cm2, expressed in decibels.
(05 Mar 2000)
substrate-level phosphorylation Synthesis of high-energy phosphate bonds through reaction of inorganic phosphate with an activated (usually) organic substrate.
(09 Oct 1997)
organic level The amount of organic matter prescribed to be left after logging.
(05 Dec 1998)
trophic level <biology> Stage in a food chain or web leading from primary producers (lowest trophic level) through herbivores to primary and secondary carnivores (consumers- highest level).
(09 Oct 1997)
lactate level A test that measures the amount of lactic acid in the blood. Lactic acid is an intermediate product of carbohydrate metabolism and is derived mainly from muscle cells and red blood cells. Exercise will normally raise lactic acid levels. Conditions of oxygen deprivation (for example shock, heart failure, lung disease) will trigger anaerobic metabolism within muscle tissue resulting in lactic acid build up in the tissues. Normal lactic acid levels are 4.5 to 19.8 mg/dl.
(27 Sep 1997)
lactic acid level <investigation> A test that measures the amount of lactic acid in the blood.
(25 Jun 1999)
free calcium level <biochemistry> The ionised calcium represents the calcium (Ca++) that is the metabolically active calcium. Normal values for ionised calcium in the bloodstream should be 4.4 to 5.3 mg/dl for adults and 4.4 to 6.0 mg/dl for children. Elevations may be seen in hyperparathyroidism, metastatic bone tumour, milk-alkali syndrome, multiple myeloma, Paget's disease, sarcoidosis, PTH-secreting tumours (paraneoplastic syndrome) and vitamin D intoxication. Lower than normal values may be seen in hypoparathyroidism, malabsorption, osteomalacia, pancreatitis, renal failure, rickets and vitamin D deficiency.
(27 Sep 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • replacement level
    Àα¸ º¸Ãæ ¼öÁØ(ÃÑÀα¸¸¦ À¯ÁöÇÏ´Â µ¥¿¡ ÇÊ¿äÇÑ Ãâ»ý·ü)
  • resistance level
    (½Ã¼¼ÀÇ)ÀúÇ×¼±(½Ã¼¼°¡ ÁÁ±â ¶§¹®¿¡ ÆÇ¸Å°¡ Ȱ¹ßÇØÁ®,±× ÀÌ»óÀÇ ½Ã¼¼ »ó½ÂÀÌ µÐÇØÁö´Â °¡°Ý ¼öÁØ)
  • sea level
    ÇØ¸é
  • spirit level
    ÁÖÁ¤ ¼öÁرâ
  • water level
    ¼öÆò¸é
  • effect
    °á°ú,¿µÇâ,È¿°ú,½Ç½Ã,ÃÊ·¡ÇÏ´Ù
  • side effect
    ºÎÀÛ¿ë
  • Compton effect
    ÄÞÇÁÅÏ È¿°ú(±¤ÀÚ¿Í ÀüÀÚÀÇ Åº¼º »ê¶õ)
  • Donald Duck effect
    µµ³Îµå ´ö È¿°ú(¿ìÁÖ ºñÇàÁßÀÇ À½¼ºÀÇ °íÀ½È­ Çö»ó)
  • Doppler effect
    µµÇ÷¯ È¿°ú 
  • Gunn effect
    ¿µ±¹ Å»ýÀÇ ¹°¸®ÇÐÀÚ J.B.Gunn ÀÇ À̸§¿¡¼­
  • Raman effect
    ¶ó¸¸ È¿°ú(ºûÀÌ Åõ¸íÇÑ ¸ÅÁúÀ» Åë°úÇÒ ¶§,»ê¶õÇÏ¿© ºûÀÇ ÀϺΠÆÄÀåÀÌ º¯È­ÇÏ´Â Çö»ó)
  • cause-and-effect
    Àΰú °ü°èÀÇ
  • echo effect
    ¸Þ¾Æ¸® È¿°ú(¾î¶² ÀÏÀÌ µÚ´Ê°Ô µÇÇ®ÀÌ µÇ°Å³ª,±× °á°ú°¡ ´Ê°Ô ³ªÅ¸³ª´Â µîÀÇ Çö»ó)
  • effect
    °á°ú;¿µÇâ;È¿°ú;À¯È¿;´À³¦;Àλó;ºû±òÀÇ ¹èÇÕ;ÃëÁö;´ëÀÇ;¿Ü°ü;°á°ú¸¦ °¡Á®¿À´Ù;´Ù;¸ñÀûÀ» ÀÌ·ç´Ù
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á